Analysts Offer Insights on NA Companies: Veeva Systems (VEEV), Blue Owl Technology Finance Corp. (OTF) and Medline (MDLN)
Companies in the NA sector have received a lot of coverage today as analysts weigh in on Veeva Systems (VEEV), Blue Owl Technology Finance Corp. (OTF) and Medline (MDLN).
Veeva Systems (VEEV)
In a report released today, Ryan MacDonald from Needham reiterated a Buy rating on Veeva Systems, with a price target of $310.00. The company’s shares closed last Wednesday at $244.91, close to its 52-week high of $258.93.
According to TipRanks.com, MacDonald is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $267.75, which is an 11.6% upside from current levels. In a report issued on August 18, TipRanks – OpenAI also upgraded the stock to Buy with a $275.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Blue Owl Technology Finance Corp. (OTF)
In a report released today, Paul Johnson from KBW maintained a Hold rating on Blue Owl Technology Finance Corp., with a price target of $12.00. The company’s shares closed last Wednesday at $11.07.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blue Owl Technology Finance Corp. with a $13.00 average price target, which is a 17.0% upside from current levels. In a report issued on August 14, RBC Capital also maintained a Hold rating on the stock with a $12.00 price target.
Medline (MDLN)
In a report released today, David Larsen from BTIG maintained a Buy rating on Medline, with a price target of $55.00. The company’s shares closed last Wednesday at $34.58, close to its 52-week low of $32.49.
According to TipRanks.com, Larsen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline with a $45.82 average price target, representing a 28.3% upside. In a report issued on August 12, J.P. Morgan also maintained a Buy rating on the stock with a $46.00 price target.
Read More on VEEV:
Disclaimer & DisclosureReport an Issue
- Veeva price target raised to $260 from $220 at Canaccord
- Veeva price target raised to $310 from $276 at Guggenheim
- Veeva price target raised to $300 from $260 at Baird
- Veeva Price Target Raised to $275 on Strong Q2 and Guidance, but AI Uncertainties Keep Rating at Hold
- Veeva price target raised to $320 from $295 at Piper Sandler
